Investigational drug · Phase 3
VGR-R01
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Bietti Crystalline Dystrophy, Inherited Retinal Diseases.
Phase 3Last checked: Nov 19, 2026Latest source record: May 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "VGR-R01"
First trial start
2024
Dec 13, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VGR-R01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Bietti Crystalline Dystrophy
- Inherited Retinal Diseases
Approved drugs for the same conditions: Rare and genetic disease · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "VGR-R01" as an intervention, largest first.
- Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients With Bietti Crystalline DystrophyPivotal-lookingActive, not recruiting
Shanghai Vitalgen BioPharma Co., Ltd.Industry
NCT06699108 · 45 participants (planned) · Start Dec 13, 2024 · Primary completion Dec 1, 2026
Drug: VGR-R01 · For: Bietti Crystalline Dystrophy; Inherited Retinal Diseases
Sites: Shanghai, China
- A Safety Study of Contralateral Eye Dosing of VGR-R01 in Participants With Bietti's Crystalline Dystrophy (BCD)Not yet recruiting
Shanghai Vitalgen BioPharma Co., Ltd.Industry
NCT07586306 · 15 participants (planned) · Start Jun 1, 2026 · Primary completion Jul 31, 2027
Drug: VGR-R01 · For: Bietti Crystalline Dystrophy
Sites: Beijing, China; Shanghai, China
Beijing Tongren HospitalAcademic, hospital or other
NCT05399069 · 3 participants (planned) · Start Sep 15, 2022 · Primary completion May 2024
Drug: VGR-R01 · For: Bietti Crystalline Dystrophy
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Preclinical studies of an AAV8-CYP4V2 gene therapy VGR-R01 for the treatment of Bietti crystalline dystrophy.
Luo W, Guo L, Lu L, et al. · Mol Ther Methods Clin Dev 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.